argenx SE (ARGX.BR)
EUR 610.0
(1.77%)
EUR 610.0
(1.77%)
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2023 | 4.11 Billion EUR | 31.2% |
| 2022 | 3.13 Billion USD | 9.96% |
| 2021 | 2.85 Billion USD | 24.75% |
| 2020 | 2.28 Billion EUR | 42.31% |
| 2019 | 1.6 Billion EUR | 142.65% |
| 2018 | 661.69 Million EUR | 48.7% |
| 2017 | 444.97 Million EUR | 300.02% |
| 2016 | 111.24 Million EUR | 121.37% |
| 2015 | 50.25 Million EUR | -29.37% |
| 2014 | 71.14 Million EUR | 105.99% |
| 2013 | 34.53 Million EUR | 50.63% |
| 2012 | 22.92 Million EUR | -28.21% |
| 2011 | 31.94 Million EUR | 160.5% |
| 2010 | 12.26 Million EUR | 0.0% |
| Year | Total Assets | Total Assets Growth |
|---|---|---|
| 2024 Q1 | - USD | -100.0% |
| 2024 Q2 | 4.79 Billion EUR | 0.0% |
| 2023 Q3 | - USD | -100.0% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q2 | 3.19 Billion USD | 0.0% |
| 2023 FY | 4.11 Billion EUR | 31.2% |
| 2023 Q4 | 4.54 Billion USD | 0.0% |
| 2022 Q3 | - USD | -100.0% |
| 2022 FY | 3.13 Billion USD | 9.96% |
| 2022 Q2 | 3.24 Billion USD | 0.0% |
| 2022 Q4 | 3.13 Billion USD | 0.0% |
| 2021 Q4 | 2.85 Billion USD | 0.0% |
| 2021 FY | 2.85 Billion USD | 24.75% |
| 2021 Q2 | 3.21 Billion USD | 0.0% |
| 2020 Q4 | 2.28 Billion EUR | 0.0% |
| 2020 Q2 | 2.27 Billion EUR | 0.0% |
| 2020 FY | 2.28 Billion EUR | 42.31% |
| 2019 FY | 1.6 Billion EUR | 142.65% |
| 2019 Q2 | 1.14 Billion EUR | 0.0% |
| 2019 Q4 | 1.43 Billion EUR | 0.0% |
| 2018 Q2 | 416.25 Million EUR | 0.0% |
| 2018 FY | 661.69 Million EUR | 48.7% |
| 2018 Q4 | 661.69 Million EUR | 0.0% |
| 2017 FY | 444.97 Million EUR | 300.02% |
| 2017 Q4 | 444.97 Million EUR | 0.0% |
| 2017 Q2 | 212.18 Million EUR | 0.0% |
| 2016 Q2 | 130.51 Million EUR | 0.0% |
| 2016 Q4 | 111.24 Million EUR | 0.0% |
| 2016 FY | 111.24 Million EUR | 121.37% |
| 2015 FY | 50.25 Million EUR | -29.37% |
| 2015 Q2 | 61.15 Million EUR | 0.0% |
| 2015 Q4 | 50.25 Million EUR | 0.0% |
| 2014 Q1 | 30.99 Million EUR | -10.26% |
| 2014 Q4 | 71.14 Million EUR | 0.0% |
| 2014 Q2 | 38 Million EUR | 22.61% |
| 2014 FY | 71.14 Million EUR | 105.99% |
| 2013 Q4 | 34.53 Million EUR | 0.0% |
| 2013 FY | 34.53 Million EUR | 50.63% |
| 2012 FY | 22.92 Million EUR | -28.21% |
| 2011 FY | 31.94 Million EUR | 160.5% |
| 2010 FY | 12.26 Million EUR | 0.0% |
| Name | Total Assets | Total Assets Difference |
|---|---|---|
| ABIONYX Pharma SA | 14.71 Million EUR | -27854.617% |
| ABIVAX Société Anonyme | 327.06 Million EUR | -1157.292% |
| Adocia SA | 24.95 Million EUR | -16377.497% |
| Aelis Farma SA | 26.28 Million EUR | -15546.757% |
| Biophytis S.A. | 11.93 Million EUR | -34351.443% |
| Advicenne S.A. | 12.4 Million EUR | -33043.582% |
| genOway Société anonyme | 31.84 Million EUR | -12814.002% |
| IntegraGen SA | 8 Million EUR | -51299.297% |
| Medesis Pharma S.A. | 1.92 Million EUR | -213368.8% |
| Neovacs S.A. | 47.53 Million EUR | -8550.985% |
| NFL Biosciences SA | 3.97 Million EUR | -103463.572% |
| Plant Advanced Technologies SA | 14.91 Million EUR | -27474.23% |
| Quantum Genomics Société Anonyme | 3.74 Million EUR | -109651.148% |
| Sensorion SA | 46.49 Million EUR | -8744.404% |
| Theranexus Société Anonyme | 7.23 Million EUR | -56715.054% |
| TME Pharma N.V. | 2.49 Million EUR | -164979.253% |
| Valbiotis SA | 33.24 Million EUR | -12268.035% |
| TheraVet SA | 7.53 Million EUR | -54479.513% |
| Valerio Therapeutics Société anonyme | 35.27 Million EUR | -11557.663% |
| BioSenic S.A. | 9.55 Million EUR | -42918.351% |
| Celyad Oncology SA | 16.28 Million EUR | -25155.646% |
| DBV Technologies S.A. | 165.65 Million USD | -2382.407% |
| Galapagos NV | 4.35 Billion EUR | 5.629% |
| Genfit S.A. | 173.87 Million EUR | -2265.03% |
| GeNeuro SA | 6.31 Million EUR | -65038.434% |
| Hyloris Pharmaceuticals SA | 47.68 Million EUR | -8524.241% |
| Innate Pharma S.A. | 184.19 Million EUR | -2132.508% |
| Inventiva S.A. | 69.13 Million EUR | -5847.619% |
| MaaT Pharma SA | 42.93 Million EUR | -9478.45% |
| MedinCell S.A. | 36.94 Million EUR | -11029.491% |
| Nanobiotix S.A. | 93.89 Million EUR | -4279.399% |
| Onward Medical N.V. | 43.62 Million EUR | -9325.208% |
| Oryzon Genomics S.A. | 106.9 Million EUR | -3746.697% |
| OSE Immunotherapeutics SA | 81.9 Million EUR | -4920.909% |
| Oxurion NV | 6.55 Million EUR | -62680.522% |
| Pharming Group N.V. | 426.33 Million EUR | -864.519% |
| Poxel S.A. | 4.82 Million EUR | -85160.713% |
| GenSight Biologics S.A. | 9.08 Million EUR | -45152.825% |
| Transgene SA | 45.21 Million EUR | -8994.2% |
| Financière de Tubize SA | 1.92 Billion EUR | -114.146% |
| UCB SA | 15.53 Billion EUR | 73.537% |
| Valneva SE | 469.39 Million EUR | -776.055% |
| Vivoryon Therapeutics N.V. | 30.82 Million EUR | -13238.494% |